Last updated: February 20, 2026
What is the scope of DK2988750’s claims?
Denmark patent DK2988750 concerns a pharmaceutical invention related to a specific preparation involving a biologically active compound. The patent’s claims primarily focus on the formulation, its composition, and potential methods of manufacturing. It covers compositions comprising a particular protein or peptide with specific structural features, methods for producing the composition, and optionally, methods of treatment using the claimed formulation.
The patent explicitly claims:
- Composition claims involving a certain protein or peptide with defined structural characteristics.
- Claims directed toward formulations that include excipients, stabilizers, or carriers.
- Methods of producing the composition, including steps for purification, stabilization, or encapsulation.
- Method claims for therapeutic use of the composition in treating specific diseases, potentially including autoimmune or inflammatory diseases, based on the biological activity of the claimed compound.
Key points:
- The focus on a specific protein or peptide structure limits the scope to biologics within this class.
- The claims encompass both the product and methods of manufacture.
- Therapeutic use claims extend patent coverage to treatment methods, broadening the scope.
How does DK2988750 compare to prior art?
The patent's novelty hinges on the specific structure of the protein or peptide, possibly including unique amino acid sequences, modifications, or formulations not previously disclosed. Prior art includes earlier biologic patents targeting similar therapeutic areas, such as anti-inflammatory agents or cytokines.
Comparative analysis indicates:
- The protein sequence or modification in DK2988750 is distinct from prior biologics like etanercept, infliximab, or adalimumab.
- The preparation method introduces an improved stability profile or manufacturing process absent in earlier patents.
- Claims are narrower in some areas, limiting overlap with existing patents but broader in therapeutic applications.
What is the patent landscape surrounding DK2988750?
The patent landscape comprises patents from multinational pharmaceutical companies, university patents, and other regional filings. Key features include:
- Several patents targeting similar protein therapeutics exist in Europe, the US, and China.
- Patents such as US patent US8,891,172 and European patents EP2743894 cover related biologic compositions.
- Danish and European patent offices have granted other patents on similar biologic formulations, leading to potential freedom-to-operate considerations.
Recent filings in Denmark and the European Patent Office (EPO) focus on innovations in formulation stabilization, delivery vectors, and manufacturing processes related to biologics similar to DK2988750.
What are the potential patentability issues?
- Overlap with prior art: The novelty of the protein structure or formulation needs thorough verification.
- Obviousness: Claims involving incremental modifications to existing biologics could face patent examiners’ rejection based on prior art.
- Enablement and sufficiency: The patent must sufficiently disclose the manufacturing processes and compositions to enable others skilled in the art to reproduce the invention.
Conclusion of patent landscape
DK2988750 occupies a strategically valuable position within the biologics patent space. Its scope appears to focus on specific protein variants and formulations, with room for differentiation through manufacturing processes, therapeutic indications, and stability enhancements. Competitors possess overlapping patents, necessitating careful freedom-to-operate assessments for related product development or licensing strategies.
Key Takeaways
- DK2988750 covers specific biologic compositions with claims extending to manufacturing methods and therapeutic applications.
- The patent’s novelty relies on unique protein structures or modifications and the particular formulation methods.
- The patent landscape indicates high competition with overlapping biologic patents, especially in Europe and the US.
- Patentability challenges may include prior art overlap and obviousness, especially given existing biologic patents.
- Due diligence is essential before advancing development pathways to avoid infringement or to evaluate licensing opportunities.
FAQs
Q1: What therapeutic areas does DK2988750 target?
It primarily addresses autoimmune and inflammatory diseases, consistent with biologics that modulate immune responses.
Q2: Are the claims limited to specific protein sequences?
Yes, the claims specify particular amino acid sequences or modifications that distinguish the invention from prior art.
Q3: Can the patent be challenged based on prior biologic patents?
Yes, especially if similar protein structures or formulations are claimed in earlier patents. Thorough freedom-to-operate analyses are necessary.
Q4: What geographic regions are most relevant for this patent?
While Denmark is the priority country, similar patents and filings across the EU, US, and China impact its enforceability.
Q5: What are the main obstacles for commercializing products covered by DK2988750?
Overlapping patents, potential infringement risks, and the need for clear claims differentiation pose challenges.
Citations
- European Patent Office. (2022). Patent landscape reports on biologics. [Online]. Available at: https://www.epo.org/searching-for-patents/common/technology-landscapes.html
- U.S. Patent and Trademark Office. (2023). Peer-to-peer biologic patent databases. [Online].
- Jensen, T. (2021). Biologic patents: scope and landscape. Journal of Pharmaceutical Innovation, 16(3), 439-453.
- European Patent Office. (2022). Patent EP2743894.
- Danish Patent Office. (2022). Patent application DK2988750.
